- Home
- QNCX vs POAS Comparison
QNCX vs POAS Comparison
Compare QNCX & POAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.80
N/A
Current Price
$3.66
Company Overview
Basic Information| Metric | QNCX | POAS |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.2M | 114.0M |
| IPO Year | 2019 | 2025 |
Fundamental Metrics
Financial Performance| Metric | QNCX | POAS |
|---|---|---|
| Price | $3.80 | $3.66 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.75 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 505.8K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $128,328.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.72 | $2.98 |
| 52 Week High | $4.55 | $4.30 |
Technical Indicators
Market Signals| Indicator | QNCX | POAS |
|---|---|---|
| Relative Strength Index (RSI) | 64.26 | N/A |
| Support Level | $3.74 | N/A |
| Resistance Level | $4.55 | N/A |
| Average True Range (ATR) | 0.46 | 0.00 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 64.39 | 0.00 |
Price Performance
Historical Comparison QNCX
POAS
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.